Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Axsome Therapeutics Commences Late-Stage Migraine Study
Axsome Therapeutics (NASDAQ: AXSM) has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine.
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Analyst Ratings for Axsome Therapeutics
Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings:
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $75
Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $55 to $75.
$1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 57.38% on an annualized basis producing an average annual return of 67.54%. Currently, Axsome Therapeutics has a market capitalization of $2.83 billion.
Boxed Warnings May Not Hinder This Depression Drug’s Broad Market Penetration, Analyst Says
Last week, Axsome Therapeutics Inc’s (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval. HC Wainwright notes that the approval comes roughly…
AMC Entertainment Price Target Cut By This Analyst, Plus DA Davidson Predicts $318 For Estée Lauder
DA Davidson cut the price target for The Estée Lauder Companies Inc. (NYSE: EL) from $342 to $318. Estée Lauder shares fell 0.4% to $264.29 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $210
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $180 to $210.
SVB Leerink Maintains Outperform on Axsome Therapeutics, Raises Price Target to $75
SVB Leerink analyst Marc Goodman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $50 to $75.